TVGN TEVOGEN BIO HOLDINGS INC

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

WARREN, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that, following the Company’s recent press release highlighting the Direct Registration System (DRS) as a secure method of share ownership, it has received a number of inquiries from shareholders seeking additional information on how to transfer their shares to a DRS account.

In response, Tevogen will provide step-by-step guidance early next week to help interested shareholders register their shares directly with the Company’s transfer agent, Continental Stock Transfer & Trust.

The Company also notes that several of its largest shareholders, both internal and external, have elected to hold their shares via DRS, underscoring their confidence in this method of direct ownership.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701



EN
02/05/2025

Underlying

TVGNTEVOGEN BIO HOLDINGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen to Share Direct Registration System (DRS) Process Details Foll...

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest WARREN, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that, following the Company’s recent press release highlighting the Direct Registration System (DRS) as a secure method of share ownership, it has received a number of inquiries from shareholders seeking additional information on how to transfer their shares to a DRS account. In response, Tevogen will provide step-by-step guidance early next week to help interested s...

May 2, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manuf...

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment WARREN, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today announced that CD8 Technology Services LLC (“CD8”) has signed a letter of intent for a facility designed to support Tevogen Bio’s cell therapy manufacturing facility. Tevogen Founder and CEO, Ryan Saadi, MD, MPH commented, “In-house manufacturing is critical to our operational efficiency, and with 74% insider ownership, we place the highest ...

April 30, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Informs Public Shareholders About DRS Accounts And Differences...

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today informed shareholders about several differences between holding shares in Direct Registration System (“DRS”) accounts and holding them in brokerage accounts. A DRS account is an alternative to using a brokerage account and Tevogen encourages shareholders to explore the differences. DRS accounts ensure your shares are registered directly in your name and not held through intermediary brok...

April 29, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Ada...

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in . Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at . Along with Dr. Ryan Saadi, the panel will als...

April 29, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in ...

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion Reflects business philosophy of commercial success through patient accessibilityRecently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and manufacturing facility; no impact on shareholder equity WARREN, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 b...

April 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch